Cubist Systematic Strategies LLC boosted its stake in COMPASS Pathways plc (NASDAQ:CMPS – Get Rating) by 102.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,412 shares of the company’s stock after purchasing an additional 26,056 shares during the quarter. Cubist Systematic Strategies LLC owned about 0.12% of COMPASS Pathways worth $552,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds have also bought and sold shares of CMPS. ARK Investment Management LLC bought a new position in COMPASS Pathways during the third quarter valued at approximately $4,169,000. Sumitomo Mitsui Trust Holdings Inc. grew its position in COMPASS Pathways by 277.6% during the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 343,194 shares of the company’s stock valued at $3,682,000 after acquiring an additional 252,303 shares during the last quarter. Renaissance Technologies LLC grew its position in COMPASS Pathways by 138.1% during the third quarter. Renaissance Technologies LLC now owns 217,368 shares of the company’s stock valued at $2,332,000 after acquiring an additional 126,068 shares during the last quarter. BlackRock Inc. grew its position in COMPASS Pathways by 27.3% during the first quarter. BlackRock Inc. now owns 275,338 shares of the company’s stock valued at $3,549,000 after acquiring an additional 59,018 shares during the last quarter. Finally, Jump Financial LLC bought a new position in COMPASS Pathways during the third quarter valued at approximately $423,000. 17.54% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of research analysts have commented on the stock. Citigroup reduced their price target on shares of COMPASS Pathways from $45.00 to $19.00 and set a “buy” rating on the stock in a research report on Wednesday, March 1st. EF Hutton Acquisition Co. I restated a “buy” rating and issued a $38.00 target price on shares of COMPASS Pathways in a report on Tuesday, February 28th. Finally, Oppenheimer cut their target price on shares of COMPASS Pathways from $55.00 to $33.00 in a report on Friday, December 9th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $47.00.
COMPASS Pathways Stock Down 2.8 %
COMPASS Pathways Profile
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder.
- Get a free copy of the StockNews.com research report on COMPASS Pathways (CMPS)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Receive News & Ratings for COMPASS Pathways Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for COMPASS Pathways and related companies with MarketBeat.com's FREE daily email newsletter.